<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">102912</article-id>
<article-id pub-id-type="doi">10.7554/eLife.102912</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.102912.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Microbiology and Infectious Disease</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Ecology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Expanding the toolbox: Novel class IIb microcins show activity against Gram-negative ESKAPE and plant pathogens</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0563-8970</contrib-id>
<name>
<surname>Mortzfeld</surname>
<given-names>Benedikt M</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<email>benedikt.mortzfeld@umassmed.edu</email>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9118-9184</contrib-id>
<name>
<surname>Bhattarai</surname>
<given-names>Shakti K</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3257-2922</contrib-id>
<name>
<surname>Bucci</surname>
<given-names>Vanni</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Microbiology, University of Massachusetts Medical School</institution>, Worcester, MA, <country>USA</country></aff>
<aff id="a2"><label>2</label><institution>Program in Microbiome Dynamics, University of Massachusetts Medical School</institution>, Worcester, MA, <country>USA</country></aff>
<aff id="a3"><label>3</label><institution>Program in Systems Biology, University of Massachusetts Medical School</institution>, Worcester, MA, <country>USA</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Zambrano</surname>
<given-names>María Mercedes</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>CorpoGen</institution>
</institution-wrap>
<city>Bogotá</city>
<country>Colombia</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Garrett</surname>
<given-names>Wendy S</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>Harvard T.H. Chan School of Public Health</institution>
</institution-wrap>
<city>Boston</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="others"><p><bold>Competing Interests</bold> The authors of this manuscript have the following competing interests: V.B. receives support from a sponsored research agreement from Vedanta Biosciences, Inc. The authors B.M.M. and S.K.B have declared that no competing interests exist.</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-11-05">
<day>05</day>
<month>11</month>
<year>2024</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP102912</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-09-14">
<day>14</day>
<month>09</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-08-29">
<day>29</day>
<month>08</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.12.05.570296"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Mortzfeld et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Mortzfeld et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-102912-v1.pdf"/>
<abstract>
<title>Abstract</title>
<p>Interspecies interactions involving direct competition via bacteriocin production play a vital role in shaping ecological dynamics within microbial ecosystems. For instance, the ribosomally-produced siderophore bacteriocins, known as class IIb microcins, affect the colonization of host-associated pathogenic <italic>Enterobacteriaceae</italic> species. Notably, to date, only five of these antimicrobials have been identified, all derived from specific <italic>Escherichia coli</italic> and <italic>Klebsiella pneumoniae</italic> strains. We hypothesized that class IIb microcin production extends beyond these specific compounds and organisms. With a customized informatics-driven approach, screening bacterial genomes in public databases with BLAST and manual curation, we have discovered twelve previously unknown class IIb microcins in seven additional <italic>Enterobacteriaceae</italic> species, encompassing phytopathogens and environmental isolates. We introduce three novel clades of microcins (MccW, MccX, and MccZ), while also identifying eight new variants of the five known class IIb microcins. To validate their antimicrobial potential, we heterologously expressed these microcins in <italic>E. coli</italic> and demonstrated efficacy against a variety of bacterial isolates, including plant pathogens from the genera <italic>Brenneria, Gibbsiella, and Rahnella</italic>. Two newly discovered microcins exhibit activity against Gram-negative ESKAPE pathogens, i.e. <italic>Acinetobacter baumannii</italic> or <italic>Pseudomonas aeruginosa</italic>, providing the first evidence that class IIb microcins can target bacteria outside of the <italic>Enterobacteriaceae</italic> family. This study underscores that class IIb microcin genes are more prevalent in the microbial world than previously recognized and that synthetic hybrid microcins can be a viable tool to target clinically relevant drug-resistant pathogens. Our findings hold significant promise for the development of innovative engineered live biotherapeutic products tailored to combat these resilient bacteria.</p>
</abstract>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors of this manuscript have the following competing interests: V.B. receives support from a sponsored research agreement from Vedanta Biosciences, Inc. The authors B.M.M. and S.K.B have declared that no competing interests exist.</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Revised manuscript after feedback during peer-review.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>A large body of theoretical and experimental work has shown that dynamics of microbiomes are shaped by the network of interbacterial interactions[<xref ref-type="bibr" rid="c1">1</xref>–<xref ref-type="bibr" rid="c4">4</xref>]. These cooperative and competitive interactions are often achieved <italic>via</italic> the secretion of cross-feeding metabolites[<xref ref-type="bibr" rid="c5">5</xref>], antimicrobial peptides[<xref ref-type="bibr" rid="c6">6</xref>] and bacterially produced small molecules[<xref ref-type="bibr" rid="c7">7</xref>, <xref ref-type="bibr" rid="c8">8</xref>] and are crucial to ecological properties including stability and ability to respond to external perturbations[<xref ref-type="bibr" rid="c9">9</xref>, <xref ref-type="bibr" rid="c10">10</xref>]. Among the competitive interactions, bacteriocin production is proposed to be a prominent mediator of microbiome dynamics[<xref ref-type="bibr" rid="c11">11</xref>] and, specifically, several reports including ours have shown that a bacteriocin subclass, Class IIb microcins, mediates <italic>Enterobacteriaceae</italic> dynamics <italic>in vivo</italic>[<xref ref-type="bibr" rid="c12">12</xref>–<xref ref-type="bibr" rid="c14">14</xref>].</p>
<p>Class IIb microcins are ribosomally synthesized bacteriocins between 5 kDa to 10 kDa in size with activity against closely related strains or species[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c15">15</xref>–<xref ref-type="bibr" rid="c18">18</xref>]. Unlike all other microcins, they carry a serine-rich C-terminal motif for a posttranslational modification with a siderophore, here an enterobactin or an enterobactin derivative, before they are secreted into the extracellular space[<xref ref-type="bibr" rid="c19">19</xref>]. Siderophores are iron-chelating molecules commonly employed by various bacteria to scavenge free iron to compete with other bacteria, particularly in resource-scarce environments such as the gastrointestinal tract[<xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c20">20</xref>] and are often associated with increased pathogenicity or virulence[<xref ref-type="bibr" rid="c21">21</xref>–<xref ref-type="bibr" rid="c23">23</xref>]. The iron chelating moiety of these posttranslationally modified antimicrobial peptides is recognized by high-affinity receptors and functions as a Trojan Horse key to susceptible bacteria as it triggers import into the periplasmic space, where the peptide inhibits the molecular target of susceptible bacteria[<xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c24">24</xref>–<xref ref-type="bibr" rid="c26">26</xref>]. Because of these features, delivery of class IIb microcins by wildtype and engineered probiotics has been recently proposed as a strategy to combat drug-resistant enteric bacteria[<xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c27">27</xref>], which is in line with a growing body of work from the past decade that explores siderophore conjugation, including with enterobactin, to specifically deliver antibiotics and other small molecules to drug-resistant Gram-negative pathogens[<xref ref-type="bibr" rid="c28">28</xref>–<xref ref-type="bibr" rid="c30">30</xref>].</p>
<p>To date only five class IIb microcins have been described and only four have been characterized in terms of their antimicrobial activity. Specifically, the class IIb microcins MccE492 and MccG492 (uncharacterized) are solely present in <italic>Klebsiella pneumoniae</italic> (<italic>Kp</italic>), whereas MccH47 is specific for <italic>Escherichia coli</italic> (<italic>Ec</italic>)[<xref ref-type="bibr" rid="c16">16</xref>]. Additionally, truncated versions of <italic>mciA</italic> (MccI47) and <italic>mcmM</italic> (MccM) are present in <italic>Kp</italic> RYC492, whereas they are intact in the <italic>Ec</italic> CA46 genome[<xref ref-type="bibr" rid="c16">16</xref>]. Interestingly, while the genes encoding for microcin posttranslational modifications are highly conserved between <italic>Ec</italic> and <italic>Kp</italic>, suggesting a conserved pathway for microcin maturation, the toxin and corresponding immunity genes are significantly more variable (<bold>Fig S1</bold>). We hypothesized that class IIb microcin production extends beyond these specific compounds and organisms and identified a total of twelve novel class IIb microcins in seven additional <italic>Enterobacteriaceae</italic> species. Utilizing heterologous expression of these compounds in our <italic>E. coli</italic> system optimized for enterobactin conjugation, we show potent antimicrobial activity by the encoded toxins against a library of bacteria, including Gram-negative ESKAPE and plant pathogens. This demonstrates that class IIb microcin genes are more prevalent in the microbial world than previously recognized and that synthetic hybrid microcins can be a viable tool to target clinically relevant drug-resistant pathogens.</p>
</sec>
<sec id="s2">
<title>Materials and Methods</title>
<sec id="s2a">
<title>Bioinformatic class IIb microcin identification</title>
<p>We developed a pipeline that by leveraging BLAST[<xref ref-type="bibr" rid="c31">31</xref>] enabled us to mine publicly available genome databases for novel, previously undescribed class IIb microcins. We included <italic>mchCDEF</italic> and <italic>mcmL</italic> for <italic>Ec</italic> as well as <italic>mceCDGHIJ</italic> for <italic>Kp</italic> for posttranslational modification and export, expecting more reliable hits for longer and functionally conserved proteins in close proximity to class IIb microcin and immunity genes. Thus, we first ran <italic>tblastn</italic>[<xref ref-type="bibr" rid="c31">31</xref>] against <italic>RefSeq</italic>[<xref ref-type="bibr" rid="c32">32</xref>], to screen for all genes related to biosynthesis pathways, known microcin genes, as well as immunity gene sequences exhibiting homology to the microcin gene clusters found in <italic>Ec</italic> CA46 and <italic>Kp</italic> RYC492. Homology to the microcin gene clusters were guided by BLAST parameters sseqid (Genome ID), pident (percentage of identical positions) along with sstart (start of alignment in Genome) and send (end of alignment position in Genome). Resulting hits were concatenated by genome ID and assessed for their proximity to one another in the genome. These gene clusters should, at best, contain all the known genes required for toxin maturation, including <italic>mchCDEF</italic> and <italic>mcmL</italic>[<xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref>]. In addition to genomic hits to the known microcins, small ORFs of 50 to 150 amino acids in size close to the biosynthesis genes were screened and annotated manually using the criteria described below as well as their domains were predicted using SMART[<xref ref-type="bibr" rid="c33">33</xref>]. The ORFs were meticulously examined and assessed against established class IIb microcin criteria known from Ec H47, <italic>Ec</italic> I47, <italic>Ec</italic> M, <italic>Kp</italic> E492, and <italic>Kp</italic> G492: (i) a serine-rich C-terminus culminating in a final serine, (ii) the presence of fewer than two cysteine residues, (iii) a signal peptide within the initial 15 amino acids ending with GG or GA, and (iv) close proximity (≤200 bp) to an ORF featuring a predicted transmembrane domain, typically encoding an immunity peptide. The identified genes were included in the pipeline’s input to expand the scope of gene detection. We repeated this process iteratively through the pipeline until no additional genes were added to the output. Subsequently, <italic>blastp</italic> was used to assess microcin similarity shown in <xref rid="tbl1" ref-type="table">Table 1</xref> and Table S1.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption><title><italic>Blastp</italic> results and closest matches to the known class IIb microcins MccE492, MccG492, MccH47, MccI47, or MccM.</title>
<p>Red color indicates no significant match found.</p></caption>
<graphic xlink:href="570296v2_tbl1.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
</sec>
<sec id="s2b">
<title>Phylogenetic analyses</title>
<p>For the native full length coding sequence of the microcin and immunity genes a codon-based sequence alignment was generated using the MUSCLE algorithm[<xref ref-type="bibr" rid="c34">34</xref>]. For phylogeny of all microcins, the nucleotide sequences without the respective signal peptides were codon-aligned. Subsequently, we determined the best fit substitution models for maximum likelihood phylogenetic analyses, resulting in the General Time Reversible model with discrete gamma distribution (GTR+G) and the Hasegawa-Kishino-Yano model with discrete gamma distribution (HKY+G), respectively. A bootstrap test with 1000 replicates for maximum likelihood and random seed was conducted for all trees. Alignment, model testing, and tree building was performed in MEGA11[<xref ref-type="bibr" rid="c35">35</xref>].</p>
</sec>
<sec id="s2c">
<title>antiSMASH analyses</title>
<p>To test if similar results of class IIb microcin identification could be obtained with automated bioinformatic tools, we ran antiSMASH 7.0[<xref ref-type="bibr" rid="c36">36</xref>], a widely used tool for microbial genome mining and biosynthetic gene cluster detection. As input, we utilized the seven genomes from the newly identified class IIb microcins: (i) <italic>Bg</italic> CP014137, (ii) <italic>Gq</italic> CP014136, (iii) <italic>Ko</italic> CP033844, (iv) <italic>Ps</italic> CP034363, (v) <italic>Ro</italic> CP008886, (vi) <italic>Se</italic> CP030220, (vii) <italic>Sf</italic> CP033055. As a positive control for the well-established microcins <italic>Kp</italic> E492 and <italic>Kp</italic> G492 as well as <italic>Ec</italic> H47 and <italic>Ec</italic> M we used the accession numbers CP127839 (<italic>Kp</italic> RYC492) and CP148105 (<italic>Ec</italic> Nissle 1917), respectively. Notably, using the “loose” setting, in none of the cases a class IIb microcin biosynthesis gene cluster was detected, nor were any microcin genes identified. This was the case for both, the novel microcins and the original, well-annotated, microcins.</p>
</sec>
<sec id="s2d">
<title>Plasmids and heterologous class IIb microcin expression</title>
<p>ORFs of identified microcin and immunity genes were codon optimized for frequent <italic>Ec</italic> codon usage without creating repetitive sequences and synthesized by Integrated DNA Technologies (Coralville, IA) with 18 bp of native 5’ upstream sequence and 20 bp of native 3’ downstream sequence, respectively. Using Gibson Assembly[<xref ref-type="bibr" rid="c37">37</xref>], the genes were cloned into our previously established <italic>Ec</italic> class IIb microcin expression system that results in mature class IIb microcins posttranslationally modified with an MGE[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c17">17</xref>]. Briefly, the antimicrobial and the immunity genes are co-expressed under the control of an arabinose-inducible pBad/araC promoter in a high copy plasmid with a pUC-derived origin of replication. All assemblies were verified using whole plasmid sequencing. DNA files for all used plasmids can be found as supplementary material.</p>
</sec>
<sec id="s2e">
<title>Static inhibition assays</title>
<p>Cultures of strains with confirmed plasmid assemblies were spread in LB agar plates containing 100 µg/ml ampicillin. In addition to a pUC19 control without microcin expression, single colonies for each microcin were picked with a sterile pipet tip and all placed into the same solid LB agar plate containing 100 µg/ml ampicillin for plasmid retention, 0.2 mM 2,2-dipyridyl to create iron-limited conditions during the growth phase, and 0.4% L-arabinose for induction of gene expression. Plates were incubated at 37°C for up to 72 h, before they were overlaid with the target bacterial isolates. Note that testing all microcin-expressing stains on the same plate allowed us to confidently assess differential inhibitory activity between all 17 tested microcins. For the overlay, the microcin-producing bacteria in the stabs were inactivated using chloroform vapors and ten minutes under ultraviolet light. Then, target bacteria were diluted 1:2000 from overnight culture in LB media containing 100 µg/ml ampicillin and 0.2 mM 2,2-dipyridyl. <italic>Ec</italic> and <italic>S. flexneri</italic> strains were diluted 1:200 to acquire dense bacterial lawns. Finally, 0.5 ml of molten agar was added to the liquid media and the resulting soft agar was spread on the plate with the inactivated bacteria and incubated for 16 h at 37°C. The pUC19 control strain was unable to create any zone of inhibition against any of the tested target bacteria.</p>
</sec>
<sec id="s2f">
<title>Relative MIC dilution factors</title>
<p>For enrichment of microcin <italic>Se</italic> G492, an MBP-microcin fusion protein was expressed from pHMT-SeG492 in <italic>E. coli</italic> BL21 cells as previously described[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c17">17</xref>]. Harvested cells were resuspended in column buffer (200 mM NaCl, 20 mM Tris-HCl, pH 7.5), lysed by sonication, and passed through a high flow amylose resin (<italic>New England Biolabs, Ipswich, MA</italic>) as recommended by the manufacturer. The protein was eluted with 10 mM maltose, cleaved with Tobacco etch virus (TEV) protease, and further processed as previously reported[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c17">17</xref>]. The relative MIC assays were conducted using sterile 96-well round bottom microplates. The plates were prepared as follows: the first row contained 20 µl of 2x LB with 0.4 mM 2,2’-dipyridyl and 20 µl of Se G492 containing solution in amylose resin elution buffer (200 mM NaCl, 20 mM Tris-HCl, 10 mM maltose, pH 7.5). All other wells were filled with 20 µl of 1x LB, 0.2 mM 2,2’-dipyridyl, and 0.5× amylose resin elution buffer, and a two-fold serial dilution was performed across the plate. The target bacteria were grown overnight in LB at 200 rpm and 37°C and were added to a final dilution of 10<sup>−4</sup> into the wells. The plates were then incubated in the dark at 37°C with gentle agitation. Relative MICs were determined as the lowest concentration at which no growth was observed after 24 hours. All reported values represent the median of at least three biological replicates.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<p>With the hypothesis that class IIb microcin production is a common trait among <italic>Enterobacteriaceae</italic>, we anticipated that the genes encoding for the antimicrobial and immunity would exhibit a high degree of dissimilarity to already known peptides as target specificity may result in accelerated adaptive coevolution[<xref ref-type="bibr" rid="c38">38</xref>]. Therefore, in addition to the known microcin and immunity genes from MccE492, MccG492, MccH47, MccI47, and MccM, in our informatic approach we included the genes that are necessary for mature class IIb microcin biosynthesis, extending our search to longer sequences for more reliable Basic Local Alignment Search Tool (BLAST) results[<xref ref-type="bibr" rid="c31">31</xref>]. Moreover, we hypothesized that the amino acid sequences of genes responsible for posttranslational modification and microcin export would be less prone to evolutionary changes, thereby maintaining the functional integrity of the gene cluster[<xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c39">39</xref>]. We then assessed their proximity in the respective genome location, because microcin genes are typically flanked by genes essential for toxin maturation[<xref ref-type="bibr" rid="c16">16</xref>]. Further, we manually assessed and annotated small open reading frames (ORFs) upstream and downstream of the maturation genes, allowing us to also identify novel class IIb microcins without significant sequence similarity to the known antimicrobials, enabling the discovery of compounds with new molecular targets or modes of action (see Methods).</p>
<p>Our informatics-driven analysis identified twelve promising class IIb microcin candidates from seven gene clusters with high similarity to <italic>Ec</italic> CA46 and <italic>Kp</italic> RYC492 in seven species across the <italic>Enterobacteriaceae</italic> family (<xref rid="fig1" ref-type="fig">Fig 1A</xref><bold>, Fig S2</bold>): (i) <italic>Brenneria goodwinii</italic> (Bg; 2; <italic>GenBank</italic>: CP014137), (ii) <italic>Gibbsiella quercinecans</italic> (<italic>Gq</italic>; 1; CP014136), (iii) <italic>Klebsiella oxytoca</italic> (<italic>Ko</italic>; 1; CP033844), (iv) <italic>Pantoea sp</italic>. (<italic>Ps</italic>; 1; CP034363), (v) <italic>Raoultella ornithinolytica</italic> (<italic>Ro</italic>; 4; CP008886), (vi) <italic>Salmonella enterica</italic> (<italic>Se</italic>; 2; CP030220), (vii) <italic>Serratia fonticola</italic> (Sf; 1; CP033055). Although it has traditionally been a defining characteristic of class IIb microcins that all required genes are encoded within the chromosome[<xref ref-type="bibr" rid="c12">12</xref>], the gene cluster we discovered for <italic>Se</italic> is situated on a 159 kbp plasmid. Phylogenetic sequence analysis of both the antimicrobial and immunity peptide genes revealed the presence of eight different clades represented in both trees, respectively (<xref rid="fig1" ref-type="fig">Fig 1B,C</xref>). Regarding the well-established class IIb microcins MccH47, MccI47, MccM, MccG492, and MccE492, we identified novel members for each group, supported by nucleotide sequence similarity, amino acid identity, the closest <italic>blastp</italic> match, and domain predictions (<xref rid="tbl1" ref-type="table">Table 1</xref><bold>, Fig S3</bold>). It is important to note that application of established tools for secondary metabolite identification (<italic>e</italic>.<italic>g</italic>., antiSMASH 7.0)[<xref ref-type="bibr" rid="c36">36</xref>] to these genomes did not yield identification of any of the old or novel microcins providing support of the relevance of our approach. In order to then ensure that these novel microcins are unique and not part of any other microcin class, we performed phylogenetic analysis for all known microcin genes from the classes I, IIa, and IIb and show distinct clustering for all newly described sequences (<bold>Fig S4</bold>). In light of this discovery, we propose a new nomenclature for class IIb microcins that includes the species initials in which they were identified (<italic>e</italic>.<italic>g</italic>., <italic>Ec, Kp</italic>), the closest relative already characterized class IIb microcin (G492, E492, H47, I47 or M), as well as the identifiers ‘A’ for antimicrobial or ‘I’ for immunity gene.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Fig 1:</label>
<caption><title>Novel class IIb microcins are found in numerous <italic>Enterobacteriaceae</italic> genomes.</title>
<p>(A) Sequence alignments of the newly identified microcin and immunity genes with the gene clusters of <italic>Ec</italic> CA46 and <italic>Kp</italic> RYC492 using Easyfig[<xref ref-type="bibr" rid="c54">54</xref>]. Antimicrobial (A) and immunity (I) genes in the center are represented by darker and lighter shades, respectively. X=mchX, I=mchI, B=mchB, E=mceE, L=mceL, M=mceM. (B,C) Phylogenetic trees of antimicrobial and corresponding immunity genes using codon-aligned nucleotide sequences with General Time Reversible model with discrete gamma distribution (GTR+G) and the Hasegawa-Kishino-Yano model with discrete gamma distribution (HKY+G), respectively. (D) MUSCLE[<xref ref-type="bibr" rid="c34">34</xref>] alignment of the amino acid sequence of the signal peptide sequence as well as the C-terminus of the antimicrobial peptides.</p></caption>
<graphic xlink:href="570296v2_fig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Based on this, the novel G492 relative found in <italic>Salmonella enterica</italic> will be called <italic>Se</italic> G492 with the antimicrobial peptide identified as <italic>Se</italic> G492A and the immunity peptide identified as Se G492I. It is worth highlighting that in the case of the G492 group, all its members have the immunity gene located downstream of the antimicrobial gene, whereas for the other clades, this arrangement is reversed. In addition to uncovering eight novel variants of the five previously characterized microcins, we have identified four additional microcins through manual curation of ORFs in proximity to the microcin maturation genes. These novel microcins, which we name microcin W (MccW), microcin X (MccX), and microcin Z (MccZ), seem to belong to three entirely new clades based on nucleotide similarity (<xref rid="fig1" ref-type="fig">Fig 1 B,C</xref>). The two members of the microcin X group, found in <italic>B. goodwinii</italic> (<italic>Bg</italic> X) and <italic>R. ornithinolytica</italic> (<italic>Ro</italic> X), only show significant similarity between one another, but not to any of the other antimicrobial or immunity peptides. This holds true for the nucleotide similarity (<xref rid="fig1" ref-type="fig">Fig 1 B,C</xref>) as well as amino acid identity and the closest <italic>blastp</italic> hits (<xref rid="fig1" ref-type="fig">Fig. 1D</xref><bold>, </bold><xref rid="tbl1" ref-type="table">Table 1</xref><bold>, Table S1</bold>). Similarly, MccW from <italic>Gibbsiella quercinecans</italic> (<italic>Gq</italic> W) does not show any sequence similarity to either the known or novel antimicrobial or immunity peptides in terms of nucleotide similarity, amino acid identity, the respective <italic>blastp</italic> hits, or phylogenetic localization (<xref rid="fig1" ref-type="fig">Fig 1</xref>,<xref rid="tbl1" ref-type="table">Table 1</xref><bold>, Table S1</bold>). Lastly, MccZ from <italic>R. ornithinolytica</italic> (Ro Z) shows insignificant amino acid similarity with Ec MA (<italic>mcmA</italic>) for the antimicrobial, whereas the immunity peptide does not have any match among the known or the novel microcins (<xref rid="fig1" ref-type="fig">Fig 1 C</xref><bold>, </bold><xref rid="tbl1" ref-type="table">Table 1</xref><bold>, Table S1</bold>). Crucially, the identification of MccX, and MccZ within the same gene clusters as representatives of the E492 (Bg E492), H47 (Ro H47), and I47 (Ro I47) groups strongly implies that they are functional components of a microcin gene cluster.</p>
<p>To test the newly identified microcins for antimicrobial activity we used our previously established <italic>Ec</italic> overexpression system[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c17">17</xref>]. All antimicrobial and immunity peptides were codon optimized, synthesized, and cloned into an inducible high copy vector (see Methods). Thus, we extracted the novel microcins out of their native genomic context of siderophore biosynthesis and transferred them into a heterologous expression background optimized for microcin-monoglycosylated enterobactin (MGE) linkage[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c17">17</xref>]. This allowed us to create hybrid compounds that could be efficiently tested for antimicrobial activity in an <italic>E. coli background</italic>. Through static plate inhibition assays involving live-producing cells[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c27">27</xref>], we successfully validated robust antimicrobial activity of eleven out of the twelve newly discovered microcins (<xref rid="fig2" ref-type="fig">Fig 2A</xref>). Notably, antimicrobial activity was only observed in iron-depleted media (<xref rid="fig2" ref-type="fig">Fig 2B,C</xref>). The hybrid microcins exhibit a range of specificities, with some inhibiting targets narrowly <italic>(e</italic>.<italic>g</italic>., <italic>Ps</italic> G492AI), while others exert a broader effect against multiple bacteria (<italic>e</italic>.<italic>g</italic>., <italic>Se</italic> G492AI). Moreover, our study also provides the first evidence of inhibitory activity by <italic>Kp</italic> G492, a microcin whose existence and function have only been proposed in the scientific literature based on genetic sequence[<xref ref-type="bibr" rid="c16">16</xref>].</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Fig 2:</label>
<caption><title>Novel class IIb microcins are effective inhibitors of <italic>Enterobacteriaceae</italic> and Gram-negative ESKAPE pathogens.</title>
<p>(A) Heatmap summarizing the inhibitory potential of known and novel class IIb microcins against a library of <italic>Enterobacteriaceae, Pseudomonadales</italic>, and Gram-positive bacteria, including multidrug-resistant isolates (red) as determined by static inhibition assays with live producing bacteria. *=activity determined through microcin purification and minimum inhibitory concentration assays[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c17">17</xref>]. (B) Relative minimum inhibitory concentrations for <italic>Se</italic> G492 against different bacterial species. Note that <italic>Se</italic> G492 is 256-times more potent against <italic>A. baumannii</italic> (BAA 1790) compared to <italic>K. pneumoniae</italic> (BAA 1705). (C) Static inhibition assays comparing <italic>Kp</italic> E492, <italic>Kp</italic> G492, <italic>Ec</italic> H47, <italic>Ec</italic> I47, <italic>Ec</italic> M, and <italic>Se</italic> G492 activity from single colony production against multidrug-resistant A. baumannii (BAA 1790) and P. aeruginosa (PA14). Note that iron-limited conditions (DP) are required for antimicrobial activity, confirming action of class IIb microcins. L-ara=L-arabinose, DP=2,2-dipyridyl, scale bars: 1 cm.</p></caption>
<graphic xlink:href="570296v2_fig2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>To this date class IIb microcins have been only shown to be very selective and only active against different species within the <italic>Enterobacteriaceae</italic> family[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c27">27</xref>]. While the activity for the novel microcins varies, we here report, for the first time, antimicrobial activity outside of the <italic>Enterobacteriaceae</italic> family utilizing hybrid antimicrobial peptides. We demonstrate that microcins <italic>Ps</italic> G492 and <italic>Se</italic> G492 have activity against Gram-negative multidrug-resistant ESKAPE pathogens with both being capable of inhibiting <italic>Acinetobacter baumannii</italic> (BAA 1790), and with microcin <italic>Se</italic> G492 alone also showing activity against <italic>Pseudomonas aeruginosa</italic> (PA14) (<xref rid="fig2" ref-type="fig">Fig 2</xref>). Specifically, compared to <italic>K. pneumoniae</italic> (BAA 1705) Se G492 is 256-times more effective against <italic>A. baumannii</italic> (BAA 1790), 128-times more effective against <italic>E. coli</italic> (BAA 196), and 8-times more effective against <italic>P. aeruginosa</italic> (PA14) (<xref rid="fig2" ref-type="fig">Fig. 2B</xref>).</p>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>With a comprehensive analysis of publicly available bacterial genomes, we unraveled twelve previously undiscovered class IIb microcins. Among these findings, we identified three novel microcin clades, specifically MccW, MccX, and MccZ. Through heterologous expression, we showed antimicrobial activity for all but one novel microcins and are the first to demonstrate activity for the known class IIb microcin <italic>Kp</italic> G492. Hence, this research demonstrates that class IIb microcin genes exhibit a higher prevalence in <italic>Enterobacteriaceae</italic> genomes than previously reported. As a result, their impact on ecological community dynamics in natural environments, including the growth of <italic>Pseudomonadales</italic> species, might be broader than previously thought. For antimicrobial activity testing, microcin and immunity genes were overexpressed recombinantly in our <italic>Ec</italic>-derived expression system optimized for microcin-MGE production[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c17">17</xref>]. The common process of posttranslational modification with the siderophore consolidated the import mechanism of the hybrid microcins towards enterobactin, the most characteristic siderophore of the <italic>Enterobacteriaceae</italic> family. This allowed us to test the target-specific antimicrobial activity of the microcins irrespective of siderophore production in the native genomic background. However, it is important to note that class IIb microcin activity is dependent on active import through siderophore receptors and consequently some of these microcins might display different activity spectrums when tested in their native genomic background of siderophore biosynthesis. Furthermore, static plate inhibition assays exhibit lower sensitivity compared to purification approaches with quantitative minimum inhibitory concentration (MIC) assays. Thus, the activity spectrums of the hybrid microcins could encompass a wider range than what has been described in this study when tested as a purified product. However, historically the microcin literature proves that ideal approaches for purification and MIC testing can vary between the antimicrobials[<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c25">25</xref>].</p>
<p>We were able to expand the origins of class IIb microcins from the enteric bacteria <italic>Ec</italic> and <italic>Kp</italic> to other members of the <italic>Enterobacteriaceae</italic> family, including well-known phytopathogens[<xref ref-type="bibr" rid="c40">40</xref>–<xref ref-type="bibr" rid="c42">42</xref>]. Specifically, <italic>B. goodwinii</italic> and <italic>G. quercinecans</italic> are associated with Acute Oak Decline (AOD) and are frequently isolated together[<xref ref-type="bibr" rid="c43">43</xref>] and the two strains containing microcin genes were isolated within the same research project. Notably, these bacteria grow synergistically[<xref ref-type="bibr" rid="c44">44</xref>], while upregulating iron transporters during co-culture[<xref ref-type="bibr" rid="c45">45</xref>], hinting at class IIb microcin-related competition. We were able to show activity of the overexpressed hybrid microcins against human-derived enteric isolates, however, their native spectrum might have evolved to target more frequently encountered strains from the genus <italic>Brenneria</italic> or <italic>Gibbsiella</italic>. Further, we demonstrated activity of several class IIb microcins against the three tree pathogen genera <italic>Brenneria, Gibbsiella</italic>, as well as <italic>Rahnella</italic>[<xref ref-type="bibr" rid="c44">44</xref>, <xref ref-type="bibr" rid="c46">46</xref>–<xref ref-type="bibr" rid="c49">49</xref>]. Thus, treatment with potent microcins, purified or produced in live bacteria, could present a viable option to target bacteria-caused plant diseases.</p>
<p>In health care settings the burden by Gram-negative ESKAPE pathogens and multidrug-resistant <italic>Enterobacteriaceae</italic> weighs heavily on modern medicine and novel antimicrobials are needed to develop new treatment options[<xref ref-type="bibr" rid="c50">50</xref>, <xref ref-type="bibr" rid="c51">51</xref>]. In addition to enteric pathogens and pathobionts, bacteria outside of the <italic>Enterobacteriaceae</italic> family have also been shown to scavenge for and to import enterobactin, including <italic>P. aeruginosa</italic> and <italic>A. baumannii</italic> [<xref ref-type="bibr" rid="c52">52</xref>, <xref ref-type="bibr" rid="c53">53</xref>]. Therefore, different siderophore conjugates could be a viable option to target these pathogens as well or to finetune the desired target range[<xref ref-type="bibr" rid="c28">28</xref>–<xref ref-type="bibr" rid="c30">30</xref>]. Antimicrobial peptides and particularly microcins are promising candidates for selective eradication of enteric pathogens and have been demonstrated to potently reduce pathogen colonization <italic>in vivo</italic>, when produced by a live probiotic[<xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>]. Here we present the most comprehensive library of class IIb microcins created so far, that is suited for heterologous expression and <italic>in vivo</italic> application for the development of novel live biotherapeutic products against drug-resistant enteric bacteria and Gram-negative ESKAPE pathogens.</p>
<p>In this study, we challenge the prevailing notion that class IIb microcin production is limited to <italic>Ec</italic> and <italic>Kp</italic>. Through comprehensive genomic analysis of publicly available bacterial genomes, coupled with heterologous overexpression, we unveiled a set undiscovered class IIb microcins across <italic>Enterobacteriaceae</italic> species. Our findings not only expand the known repertoire of class IIb microcins but also hold significant implications for synthetic hybrid compounds. We demonstrate that these newly identified class IIb microcins exert remarkable inhibitory effects on ESKAPE pathogen species when expressed in a system for enterobactin-derived conjugation. This discovery underscores their potential as agents against a broader spectrum of pathogens, including those affecting humans and plants, thus opening new avenues for antimicrobial research and applications.</p>
</sec>
<sec id="d1e1135" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="d1e1144">
<label>Supplementary Information</label>
<media xlink:href="supplements/570296_file04.docx"/>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The author would like to thank the administrative staff in the Microbiology Department at the University of Massachusetts Chan Medical School, especially Annette Bohigian, Amy Parker, Dhruti Desai, Marie Berardi, Richard Fish, and Tracey Rae, for their support.</p>
</ack>
<sec id="s5">
<title>Competing Interests</title>
<p>The authors of this manuscript have the following competing interests: V.B. receives support from a sponsored research agreement from Vedanta Biosciences, Inc. The authors B.M.M. and S.K.B have declared that no competing interests exist.</p>
</sec>
<sec id="s6">
<title>Data Availability Statement</title>
<p>The genomes are accessible with the following GenBank numbers: <italic>Brenneria goodwinii</italic> (CP014137), <italic>Gibbsiella quercinecans</italic> (CP014136), <italic>Klebsiella oxytoca</italic> (CP033844), <italic>Pantoea sp</italic>. (CP034363), <italic>Raoultella ornithinolytica</italic> (CP008886), <italic>Salmonella enterica</italic> (CP030220), <italic>Serratia fonticola</italic> (CP033055). All information is included in the manuscript or supporting files. All plasmid sequences as well as annotation files to produce <xref rid="fig1" ref-type="fig">Figs 1A</xref>, S1, S2, and S3 are available as supplementary material.</p>
</sec>
<sec id="s7">
<title>Funding Disclosure</title>
<p>This work was supported by the CDMRP PRMP W81XWH2020013 to V.B., by the NIH NIA 1R01AG075283-01A1 to V.B., and by the Deutsche Forschungsgemeinschaft (DFG) project 457837076 to B.M.M. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>B.M.M, S.K.B, and V.B conceptualized the study. S.K.B. performed bioinformatic data mining. B.M.M and V.B designed the experiments. B.M.M performed plasmid design, verification, and <italic>in vitro</italic> activity testing. B.M.M, S.K.B, and V.B wrote the manuscript.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stein</surname> <given-names>RR</given-names></string-name>, <string-name><surname>Bucci</surname> <given-names>V</given-names></string-name>, <string-name><surname>Toussaint</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Buffie</surname> <given-names>CG</given-names></string-name>, <string-name><surname>Rätsch</surname> <given-names>G</given-names></string-name>, <string-name><surname>Pamer</surname> <given-names>EG</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Ecological Modeling from Time-Series Inference: Insight into Dynamics and Stability of Intestinal Microbiota</article-title>. <source>PLoS Comput Biol</source> <year>2013</year>; <volume>9</volume>: <fpage>e1003388</fpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bucci</surname> <given-names>V</given-names></string-name>, <string-name><surname>Xavier</surname> <given-names>JB</given-names></string-name></person-group>. <article-title>Towards Predictive Models of the Human Gut Microbiome</article-title>. <source>J Mol Biol</source> <year>2014</year>; <volume>426</volume>: <fpage>3907</fpage>–<lpage>3916</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coyte</surname> <given-names>KZ</given-names></string-name>, <string-name><surname>Schluter</surname> <given-names>J</given-names></string-name>, <string-name><surname>Foster</surname> <given-names>KR</given-names></string-name></person-group>. <article-title>The ecology of the microbiome: Networks, competition, and stability</article-title>. <source>Science (1979)</source> <year>2015</year>; <volume>350</volume>: <fpage>663</fpage>–<lpage>666</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hromada</surname> <given-names>S</given-names></string-name>, <string-name><surname>Venturelli</surname> <given-names>OS</given-names></string-name></person-group>. <article-title>Gut microbiota interspecies interactions shape the response of Clostridioides difficile to clinically relevant antibiotics</article-title>. <source>PLoS Biol</source> <year>2023</year>; <volume>21</volume>: <fpage>e3002100</fpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Culp</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Goodman</surname> <given-names>AL</given-names></string-name></person-group>. <article-title>Cross-feeding in the gut microbiome: Ecology and mechanisms</article-title>. <source>Cell Host Microbe</source> <year>2023</year>; <volume>31</volume>: <fpage>485</fpage>–<lpage>499</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heilbronner</surname> <given-names>S</given-names></string-name>, <string-name><surname>Krismer</surname> <given-names>B</given-names></string-name>, <string-name><surname>Brötz-Oesterhelt</surname> <given-names>H</given-names></string-name>, <string-name><surname>Peschel</surname> <given-names>A.</given-names></string-name></person-group> <article-title>The microbiome-shaping roles of bacteriocins</article-title>. <source>Nature Reviews Microbiology 2021 19:11</source> <year>2021</year>; <volume>19</volume>: <fpage>726</fpage>–<lpage>739</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hibbing</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Fuqua</surname> <given-names>C</given-names></string-name>, <string-name><surname>Parsek</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Peterson</surname> <given-names>SB</given-names></string-name></person-group>. <article-title>Bacterial competition: surviving and thriving in the microbial jungle</article-title>. <source>Nature Reviews Microbiology 2009 8:1</source> <year>2009</year>; <volume>8</volume>: <fpage>15</fpage>–<lpage>25</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Donia</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Fischbach</surname> <given-names>MA</given-names></string-name></person-group>. <article-title>Small molecules from the human microbiota</article-title>. <source>Science (1979)</source> <year>2015</year>; <volume>349</volume>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coyte</surname> <given-names>KZ</given-names></string-name>, <string-name><surname>Rakoff-Nahoum</surname> <given-names>S.</given-names></string-name></person-group> <article-title>Understanding Competition and Cooperation within the Mammalian Gut Microbiome</article-title>. <source>Current Biology</source> <year>2019</year>; <volume>29</volume>: <fpage>R538</fpage>–<lpage>R544</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coyte</surname> <given-names>KZ</given-names></string-name>, <string-name><surname>Rao</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rakoff-Nahoum</surname> <given-names>S</given-names></string-name>, <string-name><surname>Foster</surname> <given-names>KR</given-names></string-name></person-group>. <article-title>Ecological rules for the assembly of microbiome communities</article-title>. <source>PLoS Biol</source> <year>2021</year>; <volume>19</volume>: <fpage>e3001116</fpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Niehus</surname> <given-names>R</given-names></string-name>, <string-name><surname>Oliveira</surname> <given-names>NM</given-names></string-name>, <string-name><surname>Li</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fletcher</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Foster</surname> <given-names>KR</given-names></string-name></person-group>. <article-title>The evolution of strategy in bacterial warfare via the regulation of bacteriocins and antibiotics</article-title>. <source>Elife</source> <year>2021</year>; <volume>10</volume>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sassone-Corsi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Nuccio</surname> <given-names>S-P</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hernandez</surname> <given-names>D</given-names></string-name>, <string-name><surname>Vu</surname> <given-names>CT</given-names></string-name>, <string-name><surname>Takahashi</surname> <given-names>AA</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Microcins mediate competition among Enterobacteriaceae in the inflamed gut</article-title>. <source>Nature</source> <year>2016</year>; <volume>540</volume>: <fpage>280</fpage>–<lpage>283</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mortzfeld</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Palmer</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Bhattarai</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Dupre</surname> <given-names>HL</given-names></string-name>, <string-name><surname>Mercado-Lubio</surname> <given-names>R</given-names></string-name>, <string-name><surname>Silby</surname> <given-names>MW</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Microcin MccI47 selectively inhibits enteric bacteria and reduces carbapenem-resistant Klebsiella pneumoniae colonization in vivo when administered via an engineered live biotherapeutic</article-title>. <source>Gut Microbes</source> <year>2022</year>; <volume>14</volume>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cherrak</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Salazar</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Yilmaz</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kreuzer</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hardt</surname> <given-names>WD</given-names></string-name></person-group>. <article-title>Commensal E. coli limits Salmonella gut invasion during inflammation by producing toxin-bound siderophores in a tonB-dependent manner</article-title>. <source>PLoS Biol</source> <year>2024</year>; <volume>22</volume>: <fpage>e3002616</fpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Lorenzo</surname> <given-names>V.</given-names></string-name></person-group> <article-title>Isolation and characterization of microcin E 492 from Klebsiella pneumoniae</article-title>. <source>Arch Microbiol</source> <year>1984</year>; <volume>139</volume>: <fpage>72</fpage>–<lpage>75</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vassiliadis</surname> <given-names>G</given-names></string-name>, <string-name><surname>Destoumieux-Garzón</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lombard</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rebuffat</surname> <given-names>S</given-names></string-name>, <string-name><surname>Peduzzi</surname> <given-names>J.</given-names></string-name></person-group> <article-title>Isolation and characterization of two members of the siderophore-microcin family, microcins M and H47</article-title>. <source>Antimicrob Agents Chemother</source> <year>2010</year>; <volume>54</volume>: <fpage>288</fpage>–<lpage>297</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Palmer</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Mortzfeld</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Piattelli</surname> <given-names>E</given-names></string-name>, <string-name><surname>Silby</surname> <given-names>MW</given-names></string-name>, <string-name><surname>McCormick</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Bucci</surname> <given-names>V.</given-names></string-name></person-group> <article-title>Microcin H47: A Class IIb Microcin with Potent Activity Against Multidrug Resistant Enterobacteriaceae</article-title>. <source>ACS Infect Dis</source> <year>2020</year>; <volume>6</volume>: <fpage>672</fpage>–<lpage>679</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Baquero</surname> <given-names>F</given-names></string-name>, <string-name><surname>Lanza</surname> <given-names>VF</given-names></string-name>, <string-name><surname>Baquero</surname> <given-names>MR</given-names></string-name>, <string-name><surname>del Campo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Bravo-Vázquez</surname> <given-names>DA</given-names></string-name></person-group>. <chapter-title>Microcins in Enterobacteriaceae: Peptide Antimicrobials in the Eco-Active Intestinal Chemosphere</chapter-title>. <source>Front Microbiol</source>. <year>2019</year>. <publisher-name>Frontiers Media S.A</publisher-name>., <volume>10</volume>: <fpage>2261</fpage></mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Azpiroz</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Rodríguez</surname> <given-names>E</given-names></string-name>, <string-name><surname>Laviña</surname> <given-names>M.</given-names></string-name></person-group> <article-title>The structure, function, and origin of the microcin H47 ATP-binding cassette exporter indicate its relatedness to that of colicin V</article-title>. <source>Antimicrob Agents Chemother</source> <year>2001</year>; <volume>45</volume>: <fpage>969</fpage>–<lpage>972</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patzer</surname> <given-names>SI</given-names></string-name>, <string-name><surname>Baquero</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Bravo</surname> <given-names>D</given-names></string-name>, <string-name><surname>Moreno</surname> <given-names>F</given-names></string-name>, <string-name><surname>Hantke</surname> <given-names>K.</given-names></string-name></person-group> <article-title>The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN</article-title>. <source>Microbiology (N Y)</source> <year>2003</year>; <volume>149</volume>: <fpage>2557</fpage>–<lpage>2570</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miethke</surname> <given-names>M</given-names></string-name>, <string-name><surname>Marahiel</surname> <given-names>MA</given-names></string-name></person-group>. <article-title>Siderophore-Based Iron Acquisition and Pathogen Control</article-title>. <source>Microbiology and Molecular Biology Reviews</source> <year>2007</year>; <volume>71</volume>: <fpage>413</fpage>–<lpage>451</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilson</surname> <given-names>BR</given-names></string-name>, <string-name><surname>Bogdan</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Miyazawa</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hashimoto</surname> <given-names>K</given-names></string-name>, <string-name><surname>Tsuji</surname> <given-names>Y.</given-names></string-name></person-group> <article-title>Siderophores in Iron Metabolism: From Mechanism to Therapy Potential</article-title>. <source> Trends Mol Med</source> <year>2016</year>; <volume>22</volume>: <fpage>1077</fpage>–<lpage>1090</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khasheii</surname> <given-names>B</given-names></string-name>, <string-name><surname>Mahmoodi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mohammadzadeh</surname> <given-names>A.</given-names></string-name></person-group> <article-title>Siderophores: Importance in bacterial pathogenesis and applications in medicine and industry</article-title>. <source>Microbiol Res</source> <year>2021</year>; <volume>250</volume>: <fpage>126790</fpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bieler</surname> <given-names>S</given-names></string-name>, <string-name><surname>Silva</surname> <given-names>F</given-names></string-name>, <string-name><surname>Soto</surname> <given-names>C</given-names></string-name>, <string-name><surname>Belin</surname> <given-names>D.</given-names></string-name></person-group> <article-title>Bactericidal activity of both secreted and nonsecreted microcin E492 requires the mannose permease</article-title>. <source>J Bacteriol</source> <year>2006</year>; <volume>188</volume>: <fpage>7049</fpage>–<lpage>7061</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Destoumieux-Garzón</surname> <given-names>D</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>X</given-names></string-name>, <string-name><surname>Santamaria</surname> <given-names>M</given-names></string-name>, <string-name><surname>Goulard</surname> <given-names>C</given-names></string-name>, <string-name><surname>Barthélémy</surname> <given-names>M</given-names></string-name>, <string-name><surname>Boscher</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Microcin E492 antibacterial activity: evidence for a TonB-dependent inner membrane permeabilization on Escherichia coli</article-title>. <source>Mol Microbiol</source> <year>2003</year>; <volume>49</volume>: <fpage>1031</fpage>–<lpage>1041</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rodríguez</surname> <given-names>E</given-names></string-name>, <string-name><surname>Laviña</surname> <given-names>M.</given-names></string-name></person-group> <article-title>The Proton Channel Is the Minimal Structure of ATP Synthase Necessary and Sufficient for Microcin H47 Antibiotic Action</article-title>. <source>Antimicrob Agents Chemother</source> <year>2003</year>; <volume>47</volume>: <fpage>181</fpage>–<lpage>187</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Palmer</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Piattelli</surname> <given-names>E</given-names></string-name>, <string-name><surname>McCormick</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Silby</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Brigham</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Bucci</surname> <given-names>V.</given-names></string-name></person-group> <article-title>Engineered Probiotic for the Inhibition of Salmonella via Tetrathionate-Induced Production of Microcin H47</article-title>. <source>ACS Infect Dis</source> <year>2018</year>; <volume>4</volume>: <fpage>39</fpage>–<lpage>45</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Page</surname> <given-names>MGP</given-names></string-name></person-group>. <article-title>The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics</article-title>. <source>Clinical Infectious Diseases</source> <year>2019</year>; <volume>69</volume>: <fpage>S529</fpage>–<lpage>S537</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Negash</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Norris</surname> <given-names>JKS</given-names></string-name>, <string-name><surname>Hodgkinson</surname> <given-names>JT</given-names></string-name></person-group>. <article-title>Siderophore–Antibiotic Conjugate Design: New Drugs for Bad Bugs?</article-title> <source>Molecules</source> <year>2019</year>; <volume>24</volume>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rayner</surname> <given-names>B</given-names></string-name>, <string-name><surname>Verderosa</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Ferro</surname> <given-names>V</given-names></string-name>, <string-name><surname>Blaskovich</surname> <given-names>MAT</given-names></string-name></person-group>. <article-title>Siderophore conjugates to combat antibiotic-resistant bacteria</article-title>. <source>RSC Med Chem</source> <year>2023</year>; <volume>14</volume>: <fpage>800</fpage>–<lpage>822</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boratyn</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Schäffer</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Agarwala</surname> <given-names>R</given-names></string-name>, <string-name><surname>Altschul</surname> <given-names>SF</given-names></string-name>, <string-name><surname>Lipman</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Madden</surname> <given-names>TL</given-names></string-name></person-group>. <article-title>Domain enhanced lookup time accelerated BLAST</article-title>. <source>Biol Direct</source> <year>2012</year>; <volume>7</volume>: <fpage>12</fpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Leary</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Brister</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Ciufo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Haddad</surname> <given-names>D</given-names></string-name>, <string-name><surname>McVeigh</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation</article-title>. <source>Nucleic Acids Res</source> <year>2016</year>; <volume>44</volume>: <fpage>D733</fpage>–<lpage>D745</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Letunic</surname> <given-names>I</given-names></string-name>, <string-name><surname>Khedkar</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bork</surname> <given-names>P.</given-names></string-name></person-group> <article-title>SMART: Recent updates, new developments and status in 2020</article-title>. <source>Nucleic Acids Res</source> <year>2021</year>; <volume>49</volume>: <fpage>D458</fpage>–<lpage>D460</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Edgar</surname> <given-names>RC</given-names></string-name></person-group>. <article-title>MUSCLE: multiple sequence alignment with high accuracy and high throughput</article-title>. <source>Nucleic Acids Res</source> <year>2004</year>; <volume>32</volume>: <fpage>1792</fpage>–<lpage>1797</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tamura</surname> <given-names>K</given-names></string-name>, <string-name><surname>Stecher</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>S.</given-names></string-name></person-group> <article-title>MEGA11: Molecular Evolutionary Genetics Analysis Version 11</article-title>. <source>Mol Biol Evol</source> <year>2021</year>; <volume>38</volume>: <fpage>3022</fpage>–<lpage>3027</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blin</surname> <given-names>K</given-names></string-name>, <string-name><surname>Shaw</surname> <given-names>S</given-names></string-name>, <string-name><surname>Augustijn</surname> <given-names>HE</given-names></string-name>, <string-name><surname>Reitz</surname> <given-names>ZL</given-names></string-name>, <string-name><surname>Biermann</surname> <given-names>F</given-names></string-name>, <string-name><surname>Alanjary</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>antiSMASH 7.0: new and improved predictions for detection, regulation, chemical structures and visualisation</article-title>. <source>Nucleic Acids Res</source> <year>2023</year>; <volume>51</volume>: <fpage>W46</fpage>–<lpage>W50</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gibson</surname> <given-names>DG</given-names></string-name>, <string-name><surname>Young</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chuang</surname> <given-names>RY</given-names></string-name>, <string-name><surname>Venter</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Hutchison</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>HO</given-names></string-name></person-group>. <article-title>Enzymatic assembly of DNA molecules up to several hundred kilobases</article-title>. <source>Nature Methods 2009 6:5</source> <year>2009</year>; <volume>6</volume>: <fpage>343</fpage>–<lpage>345</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paterson</surname> <given-names>S</given-names></string-name>, <string-name><surname>Vogwill</surname> <given-names>T</given-names></string-name>, <string-name><surname>Buckling</surname> <given-names>A</given-names></string-name>, <string-name><surname>Benmayor</surname> <given-names>R</given-names></string-name>, <string-name><surname>Spiers</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Thomson</surname> <given-names>NR</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Antagonistic coevolution accelerates molecular evolution</article-title>. <source>Nature 2010 464:7286</source> <year>2010</year>; <volume>464</volume>: <fpage>275</fpage>–<lpage>278</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Lynch</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ackerman</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Gout</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Long</surname> <given-names>H</given-names></string-name>, <string-name><surname>Sung</surname> <given-names>W</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>WK</given-names></string-name>, <etal>et al.</etal></person-group> <chapter-title>Genetic drift, selection and the evolution of the mutation rate</chapter-title>. <source>Nat Rev Genet</source>. <year>2016</year>. <publisher-name>Nature Publishing Group</publisher-name>., <volume>17</volume>: <fpage>704</fpage>–<lpage>714</lpage></mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Denman</surname> <given-names>S</given-names></string-name>, <string-name><surname>Brady</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kirk</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cleenwerck</surname> <given-names>I</given-names></string-name>, <string-name><surname>Venter</surname> <given-names>S</given-names></string-name>, <string-name><surname>Coutinho</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Brenneria goodwinii sp. nov., associated with acute oak decline in the UK</article-title>. <source>Int J Syst Evol Microbiol</source> <year>2012</year>; <volume>62</volume>: <fpage>2451</fpage>–<lpage>2456</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brady</surname> <given-names>C</given-names></string-name>, <string-name><surname>Denman</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kirk</surname> <given-names>S</given-names></string-name>, <string-name><surname>Venter</surname> <given-names>S</given-names></string-name>, <string-name><surname>Rodríguez-Palenzuela</surname> <given-names>P</given-names></string-name>, <string-name><surname>Coutinho</surname> <given-names>T.</given-names></string-name></person-group> <article-title>Description of Gibbsiella quercinecans gen. nov., sp. nov., associated with Acute Oak Decline</article-title>. <source>Syst Appl Microbiol</source> <year>2010</year>; <volume>33</volume>: <fpage>444</fpage>–<lpage>450</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Allahverdipour</surname> <given-names>T</given-names></string-name>, <string-name><surname>Shahryari</surname> <given-names>F</given-names></string-name>, <string-name><surname>Charkhabi</surname> <given-names>NF</given-names></string-name></person-group>. <article-title>First report of walnut bacterial canker caused by Gibbsiella quercinecans and Brenneria roseae subsp. roseae in Iran</article-title>. <source>New Dis Rep</source> <year>2020</year>; <volume>41</volume>: <fpage>12</fpage>–<lpage>12</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Denman</surname> <given-names>S</given-names></string-name>, <string-name><surname>Doonan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ransom-Jones</surname> <given-names>E</given-names></string-name>, <string-name><surname>Broberg</surname> <given-names>M</given-names></string-name>, <string-name><surname>Plummer</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kirk</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Microbiome and infectivity studies reveal complex polyspecies tree disease in Acute Oak Decline</article-title>. <source>The ISME Journal 2018 12:2</source> <year>2017</year>; <volume>12</volume>: <fpage>386</fpage>–<lpage>399</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brady</surname> <given-names>C</given-names></string-name>, <string-name><surname>Orsi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Doonan</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Denman</surname> <given-names>S</given-names></string-name>, <string-name><surname>Arnold</surname> <given-names>D.</given-names></string-name></person-group> <article-title>Brenneria goodwinii growth in vitro is improved by competitive interactions with other bacterial species associated with Acute Oak Decline</article-title>. <source>Curr Res Microb Sci</source> <year>2022</year>; <volume>3</volume>: <fpage>100102</fpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McDonald</surname> <given-names>JE</given-names></string-name>, <string-name><surname>McDonald</surname> <given-names>J</given-names></string-name>, <string-name><surname>Koskella</surname> <given-names>B</given-names></string-name>, <string-name><surname>Julian Marchesi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Doonan</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Broberg</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Host–microbiota–insect interactions drive emergent virulence in a complex tree disease</article-title>. <source>Proceedings of the Royal Society B</source> <year>2020</year>; <volume>287</volume>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brady</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hunter</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kirk</surname> <given-names>S</given-names></string-name>, <string-name><surname>Arnold</surname> <given-names>D</given-names></string-name>, <string-name><surname>Denman</surname> <given-names>S.</given-names></string-name></person-group> <article-title>Gibbsiella greigii sp. nov., a novel species associated with oak decline in the USA</article-title>. <source>Syst Appl Microbiol</source> <year>2014</year>; <volume>37</volume>: <fpage>417</fpage>–<lpage>422</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hajialigol</surname> <given-names>M</given-names></string-name>, <string-name><surname>Falahi Charkhabi</surname> <given-names>N</given-names></string-name>, <string-name><surname>Shahryari</surname> <given-names>F</given-names></string-name>, <string-name><surname>Sarikhani</surname> <given-names>S.</given-names></string-name></person-group> <article-title>Association of Rahnella victoriana, Enterobacter hormaechei subsp. hoffmannii and Citrobacter braakii with walnut decline</article-title>. <source>Scientific Reports 2023 13:1</source> <year>2023</year>; <volume>13</volume>: <fpage>1</fpage>–<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moradi-Amirabad</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Khodakaramian</surname> <given-names>G.</given-names></string-name></person-group> <article-title>Brenneria alni, causal agent bark canker of Alnus subcordata</article-title>. <source>Journal of Phytopathology</source> <year>2020</year>; <volume>168</volume>: <fpage>516</fpage>–<lpage>523</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Poret-Peterson</surname> <given-names>AT</given-names></string-name>, <string-name><surname>McClean</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kluepfel</surname> <given-names>DA</given-names></string-name></person-group>. <article-title>Complete Genome Sequences of Brenneria rubrifaciens Strain 6D370 and Brenneria nigrifluens Strain ATCC 13028, Causative Agents of Bark Cankers in Walnut</article-title>. <source>Microbiol Resour Announc</source> <year>2019</year>; <volume>8</volume>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="report"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <source>Antimicrobial resistance. Global report on surveillance</source>. <publisher-name>World Health Organization</publisher-name>. <year>2014</year>.</mixed-citation></ref>
    <ref id="c51"><label>51.</label><mixed-citation publication-type="report"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <source>Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics</source>. <publisher-name>World Health Organization</publisher-name>. <year>2017</year>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moynié</surname> <given-names>L</given-names></string-name>, <string-name><surname>Milenkovic</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mislin</surname> <given-names>GLA</given-names></string-name>, <string-name><surname>Gasser</surname> <given-names>V</given-names></string-name>, <string-name><surname>Malloci</surname> <given-names>G</given-names></string-name>, <string-name><surname>Baco</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The complex of ferric-enterobactin with its transporter from Pseudomonas aeruginosa suggests a two-site model</article-title>. <source>Nature Communications 2019 10:1</source> <year>2019</year>; <volume>10</volume>: <fpage>1</fpage>–<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subashchandrabose</surname> <given-names>S</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>S</given-names></string-name>, <string-name><surname>DeOrnellas</surname> <given-names>V</given-names></string-name>, <string-name><surname>Crepin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kole</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zahdeh</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Acinetobacter baumannii Genes Required for Bacterial Survival during Bloodstream Infection</article-title>. <source>mSphere</source> <year>2016</year>; <volume>1</volume>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sullivan</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Petty</surname> <given-names>NK</given-names></string-name>, <string-name><surname>Beatson</surname> <given-names>SA</given-names></string-name></person-group>. <article-title>Easyfig: a genome comparison visualizer</article-title>. <source>Bioinformatics</source> <year>2011</year>; <volume>27</volume>: <fpage>1009</fpage>–<lpage>1010</lpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.102912.1.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zambrano</surname>
<given-names>María Mercedes</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>CorpoGen</institution>
</institution-wrap>
<city>Bogotá</city>
<country>Colombia</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Solid</kwd>
</kwd-group>
</front-stub>
<body>
<p>This study presents <bold>important</bold> advances in the discovery and assessment of microcins that improve our understanding of their prevalence and roles. The bioinformatics analysis, expression, and antimicrobial assays are <bold>solid</bold>, although the diverging evaluations also indicated the need for additional support regarding the sequence analysis and validation to fully back some of the claims and conclusions. This study will appeal to researchers working on the discovery and analysis of novel peptide natural products.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.102912.1.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>Enterobacteriaceae produce microcins to target their competitors. Using informatics approaches, the authors identified 12 new microcins. They expressed them in E. coli, demonstrating that the microcins have antimicrobial activity against other microbes, including plant pathogens and the ESKAPE pathogens Pseudomonas aeruginosa and Acinetobacter baumannii.</p>
<p>Strengths:</p>
<p>Overall, this study has the merit of identifying new potential antimicrobial molecules that could be used to target important pathogens. The bioinformatics analysis, the expression system used, and the antimicrobial assays performed are solid, and the data presented are convincing. This work will set the basis for new studies to investigate the potential role of these microcins in vivo.</p>
<p>Weaknesses:</p>
<p>The work has been performed in vitro, which is a valid approach for identifying the antimicrobial peptides and assessing their antimicrobial activity. Future studies will need to address whether these new microcins exhibit antimicrobial activity in vivo (e.g., in the context of infection models), and to identify the targets (receptor and mechanisms of action) for the new microcins.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.102912.1.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Mortzfeld et al. describe their study of class IIb microcins. Furthering our awareness of the presence and action of microcins is an important line of research. However, several issues related to the premise, sequence analysis, and validation require attention to support the claims.</p>
<p>(1) Previous studies have been published on the broader distribution of microcins across bacteria. The software has been published for their identification. Comparison to this software and/or discussion of previous work should be included to place this work in the context of the field.</p>
<p>(2) It is not clear how immunity proteins were identified and there does not appear to be functional confirmation to show these predicted immunity proteins are real. Thus, it is premature to state that immunity genes have been found. This may also confound some of the validation studies below if proper immunity proteins have not been included.</p>
<p>(3) Please show the nt alignment used to generate the tree. Without seeing it, one would guess that the sequences are either quite similar (making the results from this study less novel) or there would be concerns that the phylogenetic relationship derived from the nt alignment is spurious.</p>
<p>(4) Figure 1 B-C: There are numerous branches that do not have phylogenetic support (values &lt;50%). These are not statistically valid phylogenetic relationships and should be collapsed. The resulting tree should be used in the description of clades.</p>
<p>(5) The discovered microcins are not being directly tested since they are expressed heterologous and reliant on non-native modification systems. The results present the statement that novel microcins have been validated. This should be described accordingly.</p>
<p>(6) The key finding of this paper is the claim that 12 novel class IIb microcins have been validated. To substantiate this claim, original images showing evidence of antibacterial activity must be made available rather than a presence/absence chart. The negative controls for this table are unclear and should be included with the original images.</p>
<p>(7) Further data for the purified microcin is needed. The purification method described is standard practice and should allow for product quantification, which should be included. Standard practice includes an SDS page showing the purity of the microcin, or at least the TEV digest to show microcin has been produced, and importantly a control sample (scrambled sequence, empty vector purification, etc) to show that observed activity (Figure 2B) is not from a purification carry over. This data should be included to support that microcin has been purified and is active.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.102912.1.sa0</article-id>
<title-group>
<article-title>Reviewer #3 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>In this study, several novel class IIb microcin biosynthetic gene clusters have been discovered by specific homology searches and manual curation. Using a specific E. coli expression system, the microcins were expressed and conjugated to monoglycosylated enterobactin as siderophore moiety. While this synthetic biology approach cannot account for other siderophores being coupled to the microcin core peptide in the original producing strains, it nonetheless allows for a general screening for the activity of the heterologously produced compounds. Through this approach, the activity of several predicted microcins has been confirmed and three novel class IIb microcin clades were identified.</p>
<p>Strengths:</p>
<p>The experimental design is sound, the results are corroborated by suitable controls, and the findings have a high level of novelty and significance. Furthermore, the comments of the initial round of peer review have been answered satisfactorily by the authors.</p>
</body>
</sub-article>
<sub-article id="sa4" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.102912.1.sa4</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mortzfeld</surname>
<given-names>Benedikt M</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0563-8970</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Bhattarai</surname>
<given-names>Shakti K</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9118-9184</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Bucci</surname>
<given-names>Vanni</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3257-2922</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>We thank the anonymous very much for dedicating their time to thoroughly review our manuscript. We sincerely appreciate their thoughtful consideration and detailed assessment. Regarding the raised concerns, we acknowledge the importance of exploring the full scope of class IIb microcins, however, we believe that in depth characterization, purification, and <italic>in vivo</italic> application of the 12 novel compounds goes beyond the scope of this short report and discovery article.</p>
<p>At the same time, the reviewers acknowledge that the analysis, experimental design, the expression system as well as the performed assays are “sound”, “convincing”, and “corroborated by suitable controls”. In the present manuscript we sought to identify novel antimicrobials and to comprehensively verify their antimicrobial activity in <italic>E. coli</italic> irrespective of the siderophore-dependent delivery mechanism. Notably, none of the reviewers questioned that we describe new antimicrobials, the characteristics we used to find them, that they are class IIb microcins, or that they do exhibit antimicrobial activity against Gram-negative ESKAPE and plant pathogens.</p>
<p>We believe that our discovery study can serve as a steppingstone towards the application of bacterially produced antimicrobial compounds to target Gram negative pathogens in numerous plant and animal species, including humans.</p>
</body>
</sub-article>
</article>